General News ThromboGenics Presenting Industry Expertise and Developments at Bio€quity Europe and Knowledge for Growth meetings in Ghent, Belgium EN May 14, 2018
News Regulated Transparency/Denominator Regulated Information / Transparency Statement EN NL April 27, 2018
General News ThromboGenics Initiates Phase 2 Clinical Study Evaluating anti-PlGF (THR-317) in combo with anti-VEGF (ranibizumab) for treatment of DME EN April 27, 2018
General News ThromboGenics announces publication in The Journal of Medicinal Chemistry of preclinical data supporting therapeutic potential of THR-149 EN April 6, 2018
General News ThromboGenics Reports Initial Data from its Clinical Study evaluating THR-317 for the Treatment of Diabetic Macular Edema (DME) EN April 4, 2018
General News Regulated Disclosure in accordance with Belgian Law of 2 May 2007 EN NL January 30, 2018
News Regulated Transparency/Denominator NOVARTIS PHARMA AG HOLDING 5.69% OF THROMBOGENICS EQUITY CAPITAL EN NL January 26, 2018
General News Regulated ThromboGenics – Patient Enrolment in Phase II CIRCLE Study Evaluating THR-409 (ocriplasmin) for Non-Proliferative Diabetic Retinopathy Discontinued due to Slow Recruitment Rate EN December 8, 2017
General News ThromboGenics announces publication in Experimental Eye Research of preclinical data supporting therapeutic potential of THR-317 in DR EN October 9, 2017
General News ThromboGenics Presenting THR-687 Preclinical Data at European Association for Vision and Eye Research (EVER) Meeting EN September 27, 2017
General News ThromboGenics Provides Business and Clinical Update at European and US Investor Meetings EN September 21, 2017
General News ONCURIOUS NV acquires unique portfolio of next-generation immuno-oncology assets from VIB EN September 1, 2017
General News New Ocriplasmin Clinical and Health Economic Data Presented at ASRS 2017 in Boston EN August 16, 2017
General News ThromboGenics and BioInvent Amending Long-Standing Monoclonal Antibody Development Agreement EN July 10, 2017
